We detected a shorter disease specific survival (DSS) in patients with a low tumor epithelial Ang-2 expression (median 1.33; 95% CI 0.50–2.16) when compared with those with an intermediate to high expression (median 2.40; 95% CI 1.86–2.94; p = 0.003; Fig. 3A). This evidence concerns the gene ANGPT2 and neoplasm.